Author:
Esserman Laura J,Ozanne Elissa M,Dowsett Mitch,Slingerland Joyce M
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988, 319: 1681-1692.
2. Jordan VC: Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer" – 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat . 1995, 36: 267-285. 10.1007/BF00713399.
3. Allred D, Bryant J, Land S, Redmond CK, Kavanagh M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from NSABP Protocol B-24. San Antonio Breast Cancer Symposium: December 13 2002; San Antonio, TX. 2002
4. Fisher B, Costantino JP, Wickerham DL, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst. 1998, 90: 1371-1388. 10.1093/jnci/90.18.1371.
5. Swain SM, Wilson JW, Mamounas EP, Grady D, Powles TJ, Cavley JA, Norton L, Nichelsen T, Bjarnason NH, Morrow M, et al: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst. 2004, 96: 516-523.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献